新研究发现,尼沃卢马布可提高高风险头癌患者的无病生存率. New study finds nivolumab boosts disease-free survival for high-risk head and neck cancer patients.

一项新的研究显示,在标准治疗中添加一种药物,称为硝硫磺,可以大大改善头部和颈部癌患者的无病存活率,他们很可能复发。 A new study shows that adding a drug called nivolumab to standard treatments can significantly improve disease-free survival for patients with head and neck cancer at high risk of relapse. 与单独接受标准治疗的患者相比,接受尼沃卢马布的患者3年无病生存率为63. 1%,而未接受尼沃卢马布的患者为52. 5%. Compared to standard treatments alone, patients who received nivolumab had a 3-year disease-free survival rate of 63.1%, compared to 52.5% for those who did not. 这表明尼沃卢马布可能成为这种患者的新标准治疗方法. This suggests nivolumab could become a new standard treatment for such patients.